CB1 cannabinoid receptor agonist inhibits matrix metalloproteinase activity in spinal cord injury: A possible mechanism of improved recovery

Neuroscience Letters

Volumn 597, Issue , 2015, Pages 19-24

  Hong, Jun ^a,b   Nandiwada, Vijaya ^d   Jones, Victoria ^d   Lu, Miaomiao ^a,c   Warner, David S ^a   Mukhopadhyay, Somnath ^d   Sheng, Huaxin ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b TANGSHAN GONGREN HOSPITAL   (China)

^c ZHENGZHOU UNIVERSITY   (China)

^d NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

Author keywords

ACEA; Agonist; Cannabinoid receptor 1; Matrix metalloproteinase 9; Spinal cord injury

Indexed keywords

5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID 1 RECEPTOR AGONIST; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; N (2 CHLOROETHYL) 5,8,11,14 EICOSATETRAENAMIDE; RIMONABANT; UNCLASSIFIED DRUG; ARACHIDONIC ACID DERIVATIVE; ARACHIDONYL-2-CHLOROETHYLAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; MATRIX METALLOPROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; HISTOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPINAL CORD INJURY; TREATMENT OUTCOME; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DRUG EFFECTS; ENZYMOLOGY; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SPINAL CORD; SPINAL CORD INJURIES;

ANIMALS; ARACHIDONIC ACIDS; MALE; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; MICE, INBRED C57BL; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SPINAL CORD; SPINAL CORD INJURIES;

EID: 84928116597     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2015.04.016     Document Type: Article

References (49)

1. Adhikary S., Li H., Heller J., Skarica M., Zhang M., Ganea D., Tuma R.F. Modulation of inflammatory responses by a cannabinoid-2-selective agonist after spinal cord injury. J. Neurotrauma 2011, 28:2417-2427.
2. Aguado T., Romero E., Monory K., Palazuelos J., Sendtner M., Marsicano G., Lutz B., Guzman M., Galve-Roperh I. The CB1 cannabinoid receptor mediates excitotoxicity-induced neural progenitor proliferation and neurogenesis. J. Biol. Chem. 2007, 282:23892-23898.
3. Ahmed M.M., King K.C., Pearce S.M., Ramsey M.A., Miranpuri G.S., Resnick D.K. Novel target for spinal cord injury related neuropathic pain. Ann. Neurosci. 2011, 18:162-167.
4. Alger B.E., Kim J. Supply and demand for endocannabinoids. Trends Neurosci. 2011, 34:304-315.
5. Arevalo-Martin A., Garcia-Ovejero D., Molina-Holgado E. The endocannabinoid 2-arachidonoylglycerol reduces lesion expansion and white matter damage after spinal cord injury. Neurobiol. Dis. 2010, 38:304-312.
6. Arevalo-Martin A., Garcia-Ovejero D., Sierra-Palomares Y., Paniagua-Torija B., Gonzalez-Gil I., Ortega-Gutierrez S., Molina-Holgado E. Early endogenous activation of CB1 and CB2 receptors after spinal cord injury is a protective response involved in spontaneous recovery. PLoS One 2012, 7:e49057.
7. Bar-Joseph A., Berkovitch Y., Adamchik J., Biegon A. Neuroprotective activity of HU-211 a novel NMDA antagonist, in global ischemia in gerbils. Mol. Chem. Neuropathol. 1994, 23:125-135.
8. Basso D.M., Fisher L.C., Anderson A.J., Jakeman L.B., McTigue D.M., Popovich P.G. Basso Mouse Scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains. J. Neurotrauma 2006, 23:635-659.
9. Belayev L., Busto R., Zhao W., Ginsberg M.D. HU-211, a novel noncompetitive N-methyl-d-aspartate antagonist, improves neurological deficit and reduces infarct volume after reversible focal cerebral ischemia in the rat. Stroke 1995, 26:2313-2319. discussion 2319-2320.
10. Brazda N., Müller H.W. Pharmacological modification of the extracellular matrix to promote regeneration of the injured brain and spinal cord. Prog. Brain Res. 2009, 175:269-281.
11. Buss A., Pech K., Kakulas B.A., Martin D., Schoenen J., Noth J., Brook G.A. Matrix metalloproteinases and their inhibitors in human traumatic spinal cord injury. BMC Neurol. 2007, 7:17.
12. de Castro R.C., Burns C.L., McAdoo D.J., Romanic A.M. Metalloproteinase increases in the injured rat spinal cord. Neuroreport 2000, 11:3551-3554.
13. de Lago E., Moreno-Martet M., Cabranes A., Ramos J.A., Fernandez-Ruiz J. Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects. Neuropharmacology 2012, 62:2299-2308.
14. Di Marzo V., Petrosino S. Endocannabinoids and the regulation of their levels in health and disease. Curr. Opin. Lipidol. 2007, 18:129-140.
15. Dubreucq S., Koehl M., Abrous D.N., Marsicano G., Chaouloff F. CB1 receptor deficiency decreases wheel-running activity: consequences on emotional behaviours and hippocampal neurogenesis. Exp. Neurol. 2010, 224:106-113.
16. Duchossoy Y., Horvat J.C., Stettler O. MMP-related gelatinase activity is strongly induced in scar tissue of injured adult spinal cord and forms pathways for ingrowing neurites. Mol. Cell. Neurosci. 2001, 17:945-956.
17. Fernandez-Lopez D., Pazos M.R., Tolon R.M., Moro M.A., Romero J., Lizasoain I., Martinez-Orgado J. The cannabinoid agonist WIN55212 reduces brain damage in an in vivo model of hypoxic-ischemic encephalopathy in newborn rats. Pediatr. Res. 2007, 62:255-260.
18. Garcia-Ovejero D., Arevalo-Martin A., Petrosino S., Docagne F., Hagen C., Bisogno T., Watanabe M., Guaza C., Di Marzo V., Molina-Holgado E. The endocannabinoid system is modulated in response to spinal cord injury in rats. Neurobiol. Dis. 2009, 33:57-71.
19. Hillard C.J. Role of cannabinoids and endocannabinoids in cerebral ischemia. Curr. Pharm. Des. 2008, 14:2347-2361.
20. Howlett A.C. The CB1 cannabinoid receptor in the brain. Neurobiol. Dis. 1998, 5:405-416.
21. Howlett A.C. Efficacy in CB1 receptor-mediated signal transduction. Br. J. Pharmacol. 2004, 142:1209-1218.
22. Hsu J.Y., Bourguignon L.Y., Adams C.M., Peyrollier K., Zhang H., Fandel T., Cun C.L., Werb Z., Noble-Haeusslein L.J. Matrix metalloproteinase-9 facilitates glial scar formation in the injured spinal cord. J. Neurosci. 2008, 28:13467-13477.
23. Hsu J.Y., McKeon R., Goussev S., Werb Z., Lee J.U., Trivedi A., Noble-Haeusslein L.J. Matrix metalloproteinase-2 facilitates wound healing events that promote functional recovery after spinal cord injury. J. Neurosci. 2006, 26:9841-9850.
24. Jackson S.J., Pryce G., Diemel L.T., Cuzner M.L., Baker D. Cannabinoid-receptor 1 null mice are susceptible to neurofilament damage and caspase 3 activation. Neuroscience 2005, 134:261-268.
25. Jensen T.S., Madsen C.S., Finnerup N.B. Pharmacology and treatment of neuropathic pains. Curr. Opin. Neurol. 2009, 22:467-474.
26. Jin K., Xie L., Kim S.H., Parmentier-Batteur S., Sun Y., Mao X.O., Childs J., Greenberg D.A. Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice. Mol. Pharmacol. 2004, 66:204-208.
27. Lichtman A.H., Martin B.R. The selective cannabinoid antagonist SR. 141716A blocks cannabinoid-induced antinociception in rats. Pharmacol. Biochem. Behav. 1997, 57:7-12.
28. Martinez-Orgado J., Fernandez-Frutos B., Gonzalez R., Romero E., Uriguen L., Romero J., Viveros M.P. Neuroprotection by the cannabinoid agonist WIN-55212 in an in vivo newborn rat model of acute severe asphyxia. Brain Res. Mol. Brain Res. 2003, 114:132-139.
29. Montecucco F., Di Marzo V., da Silva R.F., Vuilleumier N., Capettini L., Lenglet S., Pagano S., Piscitelli F., Quintao S., Bertolotto M., Pelli G., Galan K., Pilet L., Kuzmanovic K., Burger F., Pane B., Spinella G., Braunersreuther V., Gayet-Ageron A., Pende A., Viviani G.L., Palombo D., Dallegri F., Roux-Lombard P., Santos R.A., Stergiopulos N., Steffens S., Mach F. The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. Eur. Heart J. 2012, 33:846-856.
30. Mukhopadhyay S., Tulis D.A. Endocannabinoid regulation of matrix metalloproteinases: implications in ischemic stroke. Cardiovasc. Hematol. Agents Med. Chem. 2007, 5:311-318.
31. Murikinati S., Juttler E., Keinert T., Ridder D.A., Muhammad S., Waibler Z., Ledent C., Zimmer A., Kalinke U., Schwaninger M. Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J. 2010, 24:788-798.
32. Noble L.J., Donovan F., Igarashi T., Goussev S., Werb Z. Matrix metalloproteinases limit functional recovery after spinal cord injury by modulation of early vascular events. J. Neurosci. 2002, 22:7526-7535.
33. Pacher P., Batkai S., Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 2006, 58:389-462.
34. Panikashvili D., Mechoulam R., Beni S.M., Alexandrovich A., Shohami E. CB1 cannabinoid receptors are involved in neuroprotection via NF-kappa B inhibition. J. Cereb. Blood Flow Metab. 2005, 25:477-484.
35. Panikashvili D., Shein N.A., Mechoulam R., Trembovler V., Kohen R., Alexandrovich A., Shohami E. The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol. Dis. 2006, 22:257-264.
36. Panikashvili D., Simeonidou C., Ben-Shabat S., Hanus L., Breuer A., Mechoulam R., Shohami E. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001, 413:527-531.
37. Pertwee R.G. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br. J. Pharmacol. 2008, 153:199-215.
38. Preet A., Qamri Z., Nasser M.W., Prasad A., Shilo K., Zou X., Groopman J.E., Ganju R.K. Cannabinoid receptors CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis. Cancer Prev. Res. (Phila) 2011, 4:65-75.
39. Rosch S., Ramer R., Brune K., Hinz B. R(+)-methanandamide and other cannabinoids induce the expression of cyclooxygenase-2 and matrix metalloproteinases in human nonpigmented ciliary epithelial cells. J. Pharmacol. Exp. Ther. 2006, 316:1219-1228.
40. Sanudo-Pena M.C., Strangman N.M., Mackie K., Walker J.M., Tsou K. CB1 receptor localization in rat spinal cord and roots, dorsal root ganglion, and peripheral nerve. Zhongguo Yao Li Xue Bao 1999, 20:1115-1120.
41. Sheng H., Spasojevic I., Warner D.S., Batinic-Haberle I. Mouse spinal cord compression injury is ameliorated by intrathecal cationic manganese(III) porphyrin catalytic antioxidant therapy. Neurosci. Lett. 2004, 366:220-225.
42. Sheng H., Wang H., Homi H.M., Spasojevic I., Batinic-Haberle I., Pearlstein R.D., Warner D.S. A no-laminectomy spinal cord compression injury model in mice. J. Neurotrauma 2004, 21:595-603.
43. Sternlicht M.D., Werb Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 2001, 17:463-516.
44. Teasell R.W., Mehta S., Aubut J.A., Foulon B., Wolfe D.L., Hsieh J.T., Townson A.F., Short C. A systematic review of pharmacologic treatments of pain after spinal cord injury. Arch. Phys. Med. Rehabil. 2010, 91:816-831.
45. Wells J.E., Rice T.K., Nuttall R.K., Edwards D.R., Zekki H., Rivest S., Yong V.W. An adverse role for matrix metalloproteinase 12 after spinal cord injury in mice. J. Neurosci. 2003, 23:10107-10115.
46. Wiley J.L., Jefferson R.G., Grier M.C., Mahadevan A., Razdan R.K., Martin B.R. Novel pyrazole cannabinoids: insights into CB(1) receptor recognition and activation. J. Pharmacol. Exp. Ther. 2001, 296:1013-1022.
47. Yong V.W., Agrawal S.M., Stirling D.P. Targeting MMPs in acute and chronic neurological conditions. Neurotherapeutics 2007, 4:580-589.
48. Zani A., Braida D., Capurro V., Sala M. Delta9-tetrahydrocannabinol (THC) and AM 404 protect against cerebral ischaemia in gerbils through a mechanism involving cannabinoid and opioid receptors. Br. J. Pharmacol. 2007, 152:1301-1311.
49. Zhang H., Chang M., Hansen C.N., Basso D.M., Noble-Haeusslein L.J. Role of matrix metalloproteinases and therapeutic benefits of their inhibition in spinal cord injury. Neurotherapeutics 2011, 8:206-220.